Cooper Companies (NASDAQ:COO) Price Target Cut to $87.00 by Analysts at Citigroup

Cooper Companies (NASDAQ:COO) had its price objective cut by analysts at Citigroup from $88.00 to $87.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical device company’s stock. Citigroup’s target price would indicate a potential upside of 12.32% from the stock’s previous close.

Several other equities analysts have also weighed in on COO. Weiss Ratings upgraded shares of Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. Needham & Company LLC increased their target price on shares of Cooper Companies from $99.00 to $101.00 and gave the company a “buy” rating in a research note on Friday. Robert W. Baird upped their price target on Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Wall Street Zen upgraded Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, William Blair upgraded Cooper Companies to a “strong-buy” rating in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $90.79.

Cooper Companies Price Performance

Shares of COO stock traded down $2.74 during mid-day trading on Friday, hitting $77.46. 1,933,102 shares of the stock traded hands, compared to its average volume of 1,998,570. Cooper Companies has a twelve month low of $61.78 and a twelve month high of $89.83. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. The company’s 50-day simple moving average is $82.23 and its 200-day simple moving average is $75.95. The firm has a market cap of $15.11 billion, a price-to-earnings ratio of 41.20, a price-to-earnings-growth ratio of 2.34 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.07. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, equities research analysts expect that Cooper Companies will post 3.98 earnings per share for the current year.

Insiders Place Their Bets

In other Cooper Companies news, CEO Albert G. White III bought 10,000 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was acquired at an average price of $80.80 per share, with a total value of $808,000.00. Following the completion of the transaction, the chief executive officer directly owned 236,151 shares in the company, valued at approximately $19,081,000.80. This represents a 4.42% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence Erik Kurzius purchased 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were acquired at an average cost of $82.50 per share, for a total transaction of $165,000.00. Following the completion of the transaction, the director directly owned 7,777 shares of the company’s stock, valued at $641,602.50. This trade represents a 34.62% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 16,014 shares of company stock valued at $1,304,416 over the last quarter. 2.08% of the stock is owned by insiders.

Hedge Funds Weigh In On Cooper Companies

A number of large investors have recently made changes to their positions in the business. Root Financial Partners LLC boosted its holdings in shares of Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares during the period. Bell Investment Advisors Inc increased its stake in Cooper Companies by 106.3% in the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after buying an additional 219 shares during the period. True Wealth Design LLC lifted its position in Cooper Companies by 484.8% in the 4th quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock worth $38,000 after buying an additional 383 shares in the last quarter. Cromwell Holdings LLC boosted its stake in shares of Cooper Companies by 128.8% during the 4th quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock valued at $40,000 after buying an additional 273 shares during the period. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Cooper Companies during the 4th quarter valued at $41,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 results beat on the bottom line and showed margin expansion (EPS $1.10 vs. consensus $1.03; revenue up ~6.2% year‑over‑year), which management said was driven by product momentum. Read More.
• Positive Sentiment: Company raised EPS and free‑cash‑flow guidance for 2026 and highlighted strength in MyDay and MiSight products — a constructive signal for longer‑term margin and cash conversion. Read More.
• Positive Sentiment: Multiple analysts reacted positively: Barclays bumped its target to $103 (overweight) and Needham raised its target to $101; William Blair reiterated a Buy on margin/portfolio confidence — these upgrades support upside potential. Read More.
• Neutral Sentiment: Research and investor‑education pieces (Zacks) emphasize COO’s growth attributes and style scores — useful context but not market‑moving by themselves. Read More.
• Neutral Sentiment: Company published its earnings call transcript and NCC research updates on lens wear — extra detail for diligence; unlikely to drive immediate moves absent new surprises. Read More. • Read More.
• Negative Sentiment: Shares declined intraday despite the beat — coverage noted sluggish core Vision growth and regional headwinds; some investors focused on revenue or segment softness rather than EPS strength. Read More.
• Negative Sentiment: At least one large shop (Morgan Stanley) remains cautious with a Hold and a lower target ($83), reflecting concerns that recovery in some end markets and core‑vision growth may be slower than peers expect. Read More.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.